retatrutide glp-1 gip glucagon agonist is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Reduces fine lines medicaid coverage of glp Servings:30

retatrutide glp-1 gip glucagon agonist is a triple-agonist (GLP-1 + + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials Reduces fine lines medicaid coverage of glp Servings:30

medicaid coverage of glp 1 Who Gets the Shot? GLP-1 Access by State Does Medicaid Cover GLP-1 Drugs? –

One small study found that people with opioid use disorder had about 40% fewer cravings when taking liraglutide

Reduces fine lines

Servings:30

3 It led subsequently to the successful development of in vivo targeting of insulinomas by using radiolabeled exendin analogs